Bone-Rad Therapeutics, Inc.

	Steven J. Naber is President and CEO of Bone-Rad Therapeutics. Mr. Naber has been involved with the financing and operations of start-up medical device companies for the past 20 years. From October 1998, he served as the Chief Financial Officer of eyeonics, inc. until its acquisition by Bausch & Lomb in 2008. Subsequent to the acquisition, he held operational and financial roles with Bausch & Lomb Surgical, Vertos Medical, Inc., and Orthalign, Inc. From 1999-2002, while serving as the CFO of eyeonics, Mr. Naber also served as a consultant to four Orange County medical device start-up companies: Intralase went public in 2004 and was subsequently sold to Advanced Medical Optics; SenoRx also went public in 2004 and was acquired by C.R. Bard, Inc.; BioLucent was acquired by Hologix, Inc. in 2006; and Vascular Control Systems was acquired by Johnson & Johnson in 2003. Prior to joining eyeonics, from 1995 until 1997, Mr. Naber served as Vice President, Finance and Chief Financial Officer of Biopsys Medical, Inc., a publicly-held medical device company, which was acquired by Johnson & Johnson. From 1991 to 1995, Mr. Naber served as Vice President, Finance and Chief Financial Officer of Ioptex Research, Inc., an ophthalmic device company which was acquired by Allergan, Inc. From 1984 until 1990, Mr. Naber served as Vice President, Finance and Chief Financial Officer of Gradco Systems, Inc., a publicly-held office technology company. Prior to 1984, Mr. Naber held senior operational and financial positions with Mattel Electronics, Inc, and Kraft, Inc. Mr. Naber received a B.B.A. in Accounting from the University of Iowa.
	Dr. Harry B. Skinner, M.D., Ph.D. is Chairman and a co-founder of Bone-Rad Therapeutics, as well as a co-inventor of radioactive bone cement. He has been a Professor of Orthopaedic Surgery in the University of California system for over 20 years. Dr. Skinner is an orthopaedic surgeon and a materials scientist and has well over 100 peer-reviewed publications. Dr. Skinner has had experience with two start-ups, Norian (manufacturer of an injectable bone substitute that was eventually sold to Synthes, Inc.) and Kyphon (now a multi-billion-dollar corporation marketing supplies for kyphoplasty). He has served as a panel member for the FDA, evaluating various orthopaedic devices. Dr. Skinner brings his knowledge of the orthopaedic market, orthopaedic surgery, materials science, and regulatory issues to Bone-Rad Therapeutics.
	Dr. Tadashi S. Kaneko, Ph.D. is Chief Financial Officer, Secretary, and a co-founder of Bone-Rad Therapeutics. He is a mechanical engineer, biomedical engineer, and machinist who has worked with Dr. Keyak since April 2000. He has experience designing and fabricating equipment for orthopaedic research and is familiar with the use of bone cement to repair bone with tumors. Dr. Kaneko has 12 peer-reviewed publications and abstracts and recently completed his doctoral study in Biomedical Engineering at the University of California at Irvine. A significant portion of Dr. Kaneko’s doctoral dissertation involved the development and evaluation of a radiation transport modeling method for predicting dose distributions in vertebrae injected with radioactive bone cement.
	Dr. Joyce H. Keyak, Ph.D. is a co-founder of Bone-Rad Therapeutics and a co-inventor of radioactive bone cement. She has been the driving force for R&D of products and procedures related to internal radiation therapy, i.e. “brachytherapy”, for bone. Dr. Keyak secured $760,000 from the Department of Defense Breast Cancer Research Program to develop devices and procedures for combining brachytherapy with a bone-strengthening procedure for the spine, vertebroplasty or kyphoplasty. Dr. Keyak has over 13 years experience as an Associate Professor in Residence in the Departments of Radiological Sciences, Orthopaedic Surgery, Biomedical Engineering, and Mechanical and Aerospace Engineering at the University of California at Irvine (UCI). She heads the Bone Biomechanics Laboratory at UCI and is an expert on the structure and mechanics of bone. Dr. Keyak has over 50 peer-reviewed publications.
	Dr. Varun Sehgal, Ph.D. is a co-founder of Bone-Rad Therapeutics and a medical physicist with experience developing brachytherapy techniques. Dr. Sehgal was responsible for the initial “proof of concept” that demonstrated feasibility of using radioactive bone cement to treat bone. He is an Assistant Professor of Radiation Oncology at the University of California at Irvine (UCI), is board certified in Therapeutic Radiological Physics by the American Board of Radiology, and is regularly involved in patient treatment at UCI. He also serves on the Special Brachytherapy Modalities Working Group of the American Association of Physicists in Medicine (AAPM). Dr. Sehgal oversees the radiation aspects of the business, such as product development, dosing, radiation shielding, etc. Dr. Sehgal has 20 publications/presentations at national meetings and symposiums for medical physics and radiation oncology.